（编辑 任世碧） 证券日报网讯 8月4日晚间，奥锐特发布公告称，截至2025年7月31日，公司通过上海证券交易所交易系 统以集中竞价交易方式已累计回购公司股份141.42万股，占公司目前总股本的比例为0.35%。 ...

Group 1 - Weihai Guangtai reported a net profit of 83.32 million yuan for the first half of 2025, a year-on-year decrease of 22.41%, while total revenue reached 1.425 billion yuan, an increase of 10.91% [1] - Haowei Group expects a net profit increase of 39.43% to 49.67% for the first half of 2025, estimating a profit range of 1.906 billion to 2.046 billion yuan [1] - Tengda Construction won a bid for a project worth 118 million yuan, with a construction period of 500 calendar days [1] Group 2 - Shanda Power plans to use up to 520 million yuan of idle raised funds for cash management, investing in safe and liquid products with a term not exceeding 12 months [3] - Rundu Co., Ltd. received approval for the listing application of its chemical raw material drug, which is suitable for surgical treatment in adults and children over one month old [4] - Zhongyuan Qihua's subsidiary's clinical trial application for a drug aimed at treating pulmonary fibrosis has been accepted [4] Group 3 - Shanghai Xiba plans to establish a joint venture with Yuyuan Rare Earth, focusing on advanced materials for lithium-ion solid-state batteries, with a registered capital of 200 million yuan [6] - Aorite's senior management plans to reduce their holdings by up to 62,500 shares, accounting for 0.02% of the company's total equity [7] - Yipin Hong's subsidiary's clinical trial application for a new oral drug for endometriosis has been accepted [8] Group 4 - Haya Pharmaceutical plans to lease idle assets covering 22,671.39 square meters for a period of 10 years [9] - Southern Precision Engineering applied for a credit limit of 50 million yuan from a bank for operational purposes [11] - Jindawei's subsidiary established a joint venture with a registered capital of 5 million yuan, focusing on the sale of food additives and health products [12] Group 5 - Gaode Infrared signed a product order contract worth 307 million yuan, expected to account for 11.46% of the company's audited revenue for 2024 [13] - Xichang Electric will implement a low valley electricity price policy starting September 1, 2025, which is expected to reduce net profit by approximately 5.55 million yuan [14] - Huyou Pharmaceutical's first subject has been dosed in a Phase I clinical trial for a drug targeting advanced solid tumors [16] Group 6 - Chuanheng Co., Ltd. received a patent for a dust removal system in mining operations [17] - Spring Wind Power's application for issuing convertible bonds has been accepted by the Shanghai Stock Exchange [18] - Liuyao Group plans to repurchase shares worth between 100 million and 200 million yuan [19] Group 7 - Baiyun Electric has obtained a commitment letter for a stock repurchase loan of up to 18 million yuan [20] - Tonghe Pharmaceutical received a patent for a method of preparing an intermediate for a migraine treatment drug [21] - Tainkang's subsidiary's Phase II clinical trial for a drug for vitiligo has shown significant efficacy and safety [23] Group 8 - Yuhua Tian's secretary and deputy general manager resigned for personal reasons [24] - Heizhima's controlling shareholder is planning a change in control, leading to a temporary suspension of stock trading [25] - Keda Li's subsidiary completed a capital increase, raising its registered capital to 700 million yuan [26] Group 9 - Fangda Special Steel's shareholder plans to reduce holdings by up to 1% of the company's shares [28] - ST Pava's director is under investigation for alleged embezzlement, but the company's operations remain normal [29] - Jiachuan Video's controlling shareholder is planning a change in control, resulting in a temporary stock suspension [32] Group 10 - Danhua Technology will change its stock name to Jinmei Technology starting August 7, 2025, due to a relocation of its registered office [33] - Morning Wind Technology's shareholder plans to reduce holdings by up to 1% of the company's shares [34] - Leshan Electric will adjust residential gas prices starting September 1, 2025, which is expected to increase gross profit by approximately 2.7 million yuan [35] Group 11 - SAIC Motor reported a total vehicle sales of 337,500 units in July 2025, a year-on-year increase of 34.22%, with significant growth in new energy vehicle sales [36] - LIGONG Navigation's shareholders plan to reduce holdings by up to 3% of the company's shares [37] - United Imaging's employee stock ownership platform plans to reduce holdings by up to 1.62% of the company's shares [38] Group 12 - Beiqi Blue Valley's subsidiary reported a 6.38% decline in sales in July 2025 [39] - Watson Bio's clinical research application for an mRNA vaccine has been accepted [40]

证券代码：605116 证券简称：奥锐特 公告编号：2025-054 债券代码：111021 债券简称：奥锐转债 奥锐特药业股份有限公司 1 关于部分高管减持股份计划公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 减持计划的主要内容 因个人资金需求，上述减持主体计划自本公告发布之日起 15 个交易日后的 3 个月内（窗口期不减持），拟通过集中竞价方式减持其所持有的公司股份，上 述减持主体拟减持的股份数量不超过 62,500 股，不超过公司总股本的 0.02%。 根据上海证券交易所发布的《上海证券交易所上市公司自律监管指引第 15 号——股东及董事、高级管理人员减持股份（2025 年 3 月修订）》的规定，上述 减持主体本次拟减持的股份数量不超过其所持有公司股份总数的 25%。自本公告 披露之日起至减持计划的实施期间，若公司发生派发红利、送红股、转增股本、 增发新股或配股等股份变动事项，拟减持数量将进行相应调整，减持价格将按照 减持实施时的市场价格确定。 一、减持主体的基本情况 | | | 重要内容提示： 高管持 ...

一、 回购股份的基本情况 2025 年 1 月 21 日，奥锐特药业股份有限公司（以下简称"公司"）召开第三 届董事会第十二次会议，会议以 9 票同意、0 票反对、0 票弃权审议通过了《关于 以集中竞价交易方式回购公司股份方案的议案》，同意公司以集中竞价交易方式回 购公司股份，回购的股份全部用于转换公司可转债。本次回购股份的资金总额为 不低于人民币 6,000 万元（含），不高于人民币 12,000 万元（含），回购价格不超 过人民币 25.00 元/股（含），回购期限自公司董事会审议通过回购方案之日起不 超过 12 个月。 | | | 奥锐特药业股份有限公司 关于以集中竞价交易方式回购公司股份的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 回购方案首次披露日 | 2025/1/22 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 回购方案实施期限 | 2025 年 1 月 | 月 | 21 | 日~2026 | ...

Group 1 - The company Aorite (SH 605116, closing price: 23.69 CNY) announced on August 4 that as of July 31, 2025, it has repurchased a total of 1.4142 million shares through the Shanghai Stock Exchange trading system, accounting for 0.35% of the current total share capital, with a total expenditure of approximately 28.22 million CNY [2] - The highest repurchase price was 21.3 CNY per share, while the lowest was 18.83 CNY per share [2] Group 2 - For the year 2024, the revenue composition of Aorite is as follows: self-produced raw materials and intermediates accounted for 77.29%, formulations accounted for 14.91%, trade accounted for 7.55%, and other businesses accounted for 0.25% [2]

格隆汇8月4日丨奥锐特(605116.SH)公布，截至2025年7月31日，公司通过上海证券交易所交易系统以集 中竞价交易方式已累计回购公司股份141.42万股，占公司目前总股本的比例为0.35%，回购成交的最高 价为21.30元/股，最低价为18.83元/股，支付的资金总额为人民币28,220,158.00元（不含交易费用）。 ...

Group 1 - The core point of the article is that senior management personnel Zhao Zhenping of Aorite (605116.SH) plans to reduce his shareholding due to personal financial needs [1] - Zhao Zhenping intends to reduce his holdings by no more than 62,500 shares, which accounts for 0.02% of the company's total share capital [1] - The reduction will take place within three months after a 15 trading day period from the announcement date, during which no shares will be sold [1]

奥锐特8月4日公告，公司高级管理人员赵珍平因个人资金需求，计划自公告发布之日起15个交易日后的 3个月内，通过集中竞价方式减持公司股份不超过6.25万股，即不超过公司总股本的0.02%。减持价格将 根据减持实施时的市场价格确定。本次减持计划实施具有不确定性。 ...

Core Viewpoint - As of August 1, 2025, Aorite (605116) closed at 23.96 yuan, down 0.58%, with a turnover rate of 1.19% and a trading volume of 47,500 hands, resulting in a transaction amount of 114 million yuan [1] Trading Information Summary - On August 1, Aorite's capital flow indicated a net outflow of 5.71 million yuan from main funds, accounting for 5.0% of the total transaction amount [2][3] - Retail investors showed a net inflow of 7.87 million yuan, representing 6.88% of the total transaction amount [2] Company Announcement Summary - Aorite Pharmaceutical Co., Ltd. announced the redemption of part of its idle raised funds for cash management, allowing the use of up to 300 million yuan of idle raised funds, with a rolling usage limit valid for 12 months from the approval date of the third board meeting [2] - On June 30, 2025, the company invested 40 million yuan in a structured deposit product from Industrial Bank, which had a term from July 1 to July 31, 2025, and has since been redeemed, yielding a profit of 62,500 yuan [2][3]

Core Insights - The report highlights that in 2024, the total salary for A-share listed company secretaries reached 4.086 billion yuan, with an average annual salary of 708,000 yuan [1] - A total of 1,144 company secretaries earned over 1 million yuan, accounting for more than 21% of the total [1] Salary Distribution - The average annual salary for company secretaries in the A-share raw material pharmaceutical sector is 608,400 yuan [2] - The distribution of salaries shows that 49% earn below 500,000 yuan, 40% earn between 500,000 and 1 million yuan, and 11% earn above 1 million yuan [2] - The top five highest-paid company secretaries have annual salaries of 1.9309 million yuan, 1.514 million yuan, 1.2 million yuan, 1.17 million yuan, and 1.1 million yuan respectively [2] Age and Education Distribution - Company secretaries aged between 30 and 50 constitute 60% of the market, while those over 50 account for 38%, and those aged 30 or below make up 2% [1] - More than half of the company secretaries hold a bachelor's degree, with 9% having an associate degree, 52% a bachelor's degree, and 39% a master's degree [1] Investor Engagement - There is significant variation in the number of investor meetings held by companies, with 43% of companies hosting fewer than 10 meetings annually [2] - The top five companies with the most investor meetings conducted 520, 437, 325, 323, and 291 meetings respectively [3]